Aerogen Pharma Enters an Exclusive Agreement with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
Shots:
- Aerogen Pharma to receive $20M up front and $10M equity in Nuance, along with a sum of $182.5M as potential development, regulatory, & commercial milestone payments, plus royalties on net sales within the territory
- The agreement grants Nuance the exclusive rights to develop and commercialize AeroFact in Greater China (Mainland China, Taiwan, Hong Kong, and Macau)
- AeroFact is a nasally inhaled surfactant based on a combination of the bovine lung surfactant Alveofact with a precise nasal delivery system containing Aerogen's next gen "PDAP" delivery technology and a touch-screen controller interface
Ref: PR Newswire | Image: Aerogen
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com